Home › Compare › TRCLF vs ABBV
TRCLF yields 3.47% · ABBV yields 3.06%● Live data
📍 TRCLF pulled ahead of the other in Year 2
Combined, TRCLF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TRCLF + ABBV for your $10,000?
transcosmos inc. provides business outsourcing services worldwide. The company offers outsourcing services to back-office operations, including accounting/finance and human resources; order placement services; operation and maintenance of IT systems; and mechanical, architectural, and other design operations. It also provides contract center services, such as outsourcing services for customer support operations comprising dealing with inquires and complaints from consumers, providing products and services information to the customers, and supporting marketing and sales. In addition, the company offers digital marketing services that make use of Internet infrastructures, Internet promotions, Website design and operations, omni cahnnel marketing, and analysis and research services. Further, it provides e-commerce services, including various functions required for e-commerce, such as e-commerce Website development and operation, fulfillment, customer care, online promotions, and analysis services. The company serves financial, telecommunication, high-tech, medical, cosmetics, distribution, automobile, and airline industries, as well as the public sector. transcosmos inc. was founded in 1966 and is based in Tokyo, Japan.
Full TRCLF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.